Processa Pharmaceuticals logo
Processa Pharmaceuticals PCSA
$ 1.59 -4.22%
report update icon

Quarterly report 2026-Q3
added 11-13-2026

Processa Pharmaceuticals EBITDA | PCSA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Processa Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-14 M -12.1 M -11.5 M -26.7 M -12.1 M -5.63 M -3.13 M -3.89 M -1.8 M -71.4 K -748 K -2.49 M -2.55 M -2.16 M -1.11 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-71.4 K -26.7 M -6.66 M

Quarterly EBITDA Processa Pharmaceuticals

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-184 M -2.34 M -3.33 M -3.7 M -3.49 M -3.95 M -2.85 M - -3.42 M -3.08 M -2.81 M -2.47 M -2.17 M -2.71 M -4.11 M -12.9 M -5.86 M -4.97 M -3.03 M -3.17 M -2.92 M -3.26 M -1.99 M - -2.95 M -603 K -787 K -713 K -805 K -938 K -684 K -543 K -863 K -1.23 M -1.29 M -571 K -716 K -280 K -234 K - 159 159 159 - 10.1 K 23.9 K 19.1 K - 22.4 K 23.4 K 21.8 K - 14.5 K 13.2 K 13 K - 4.68 K 715 - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
23.9 K -184 M -5.41 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
-31.5 M $ 0.79 -2.58 % $ 36.6 M usaUSA
Geron Corporation Geron Corporation
GERN
-68.1 M $ 0.87 -4.76 % $ 580 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
74 M $ 11.54 -5.18 % $ 7.95 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-159 M $ 4.65 -8.46 % $ 339 M usaUSA
Genmab A/S Genmab A/S
GMAB
6.57 B $ 50.36 -1.93 % $ 3.26 B danmarkDanmark
Gossamer Bio Gossamer Bio
GOSS
-171 M $ 10.69 -4.81 % $ 2.44 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
1.19 B $ 8.14 -0.73 % $ 5.53 B spainSpain
Liquidia Corporation Liquidia Corporation
LQDA
-49.8 M $ 54.39 -3.96 % $ 4.68 B usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
7.93 B $ 47.8 -0.05 % $ 194 B britainBritain
MediciNova MediciNova
MNOV
-13.3 M $ 1.3 2.36 % $ 63.8 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
906 M $ 56.23 -3.59 % $ 4.47 B usaUSA
Pulmatrix Pulmatrix
PULM
-1.29 M $ 1.24 -12.34 % $ 4.53 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
-44.9 M $ 1.05 -3.67 % $ 70.7 M germanyGermany
Immunome Immunome
IMNM
-222 M $ 15.69 -5.54 % $ 1.37 B usaUSA
Immuron Limited Immuron Limited
IMRN
-5.34 M $ 0.9 5.87 % $ 208 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
1.61 B $ 114.5 -1.19 % $ 22.4 B usaUSA
INmune Bio INmune Bio
INMB
-47.3 M $ 0.82 -8.41 % $ 20.3 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
71.8 B $ 14.88 0.24 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
4.12 B $ 920.38 -0.22 % $ 96.3 B usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
-204 M $ 26.58 -2.37 % $ 4.25 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
-14.7 M $ 1.06 -10.92 % $ 48.4 M israelIsrael
Ironwood Pharmaceuticals Ironwood Pharmaceuticals
IRWD
99.6 M $ 4.68 -0.53 % $ 757 M usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
-38.8 M $ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
-431 M $ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
-21 M $ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
-544 M $ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
6.59 B $ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-47.1 M $ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
4.43 M $ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
-155 M $ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
78.8 M $ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-467 M $ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
1.56 B $ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
-23.5 M $ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
12.8 M $ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
-86.9 M $ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
106 M $ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
-37.1 M $ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
-2.58 M - -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
-192 M $ 112.31 -3.84 % $ 7.3 B usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
-87 M - - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-121 M $ 1.29 -2.28 % $ 164 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
232 M $ 32.58 -1.21 % $ 1.87 B usaUSA
Ardelyx Ardelyx
ARDX
-37.9 M $ 2.99 -2.25 % $ 721 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
24.8 M $ 0.39 -8.41 % $ 100 M usaUSA
Alector Alector
ALEC
-150 M $ 2.34 1.52 % $ 241 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
-103 M $ 1.06 3.43 % $ 56.9 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
451 M $ 21.12 -1.26 % $ 6.62 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-37.8 M $ 4.03 -1.11 % $ 772 M canadaCanada
Agenus Agenus
AGEN
-10.2 M $ 5.97 -2.85 % $ 178 M usaUSA